Abbott Laboratories (ABT) : Johanson Financial Advisors scooped up 26 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 5,214 shares of Abbott Laboratories which is valued at $212,679.Abbott Laboratories makes up approximately 0.23% of Johanson Financial Advisors’s portfolio.
Other Hedge Funds, Including , Vigilant Capital Management boosted its stake in ABT in the latest quarter, The investment management firm added 590 additional shares and now holds a total of 193,415 shares of Abbott Laboratories which is valued at $7,889,398. Abbott Laboratories makes up approx 1.42% of Vigilant Capital Management’s portfolio.Toth Financial Advisory Corp boosted its stake in ABT in the latest quarter, The investment management firm added 11,351 additional shares and now holds a total of 149,703 shares of Abbott Laboratories which is valued at $6,134,829. Abbott Laboratories makes up approx 1.85% of Toth Financial Advisory Corp’s portfolio.Gradient Investments reduced its stake in ABT by selling 109,203 shares or 97.94% in the most recent quarter. The Hedge Fund company now holds 2,296 shares of ABT which is valued at $99,876. Abbott Laboratories makes up approx 0.01% of Gradient Investments’s portfolio.Chevy Chase Trust Holdings reduced its stake in ABT by selling 31,106 shares or 2.24% in the most recent quarter. The Hedge Fund company now holds 1,355,680 shares of ABT which is valued at $57,941,763. Abbott Laboratories makes up approx 0.32% of Chevy Chase Trust Holdings’s portfolio.Cullinan Associates Inc reduced its stake in ABT by selling 17,450 shares or 5.9% in the most recent quarter. The Hedge Fund company now holds 278,300 shares of ABT which is valued at $11,894,542. Abbott Laboratories makes up approx 1.02% of Cullinan Associates Inc’s portfolio.
Abbott Laboratories closed down -0.19 points or -0.46% at $40.79 with 88,18,965 shares getting traded on Friday. Post opening the session at $41.17, the shares hit an intraday low of $40.77 and an intraday high of $41.53 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.